Hematologic Disorders Archives - Page 80 of 82 - MPR

Hematologic Disorders

Phase 3 Trial Update of Eliquis for Prevention of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation

Bristol-Myers Squibb and Pfizer announced that the reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with Eliquis (apixaban) compared to warfarin (Coumadin; Bristol-Myers Squibb) in the Phase 3 ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation; these were results from a subanalysis from the study.

VTE Risk Varies by Hormone Therapy Formulation

VTE Risk Varies by Hormone Therapy Formulation

The risk of venous thromboembolism (VTE) in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest VTE risk seen in users of oral estrogen-progestin HT containing medroxyprogesterone acetate.